Identifying genes involved in the development of cancer is crucial to fully understanding cancer biology, for developing novel therapeutics for cancer treatment and for providing methods for cancer prevention and early diagnosis. The use of polymorphic markers, in particular single nucleotide polymorphisms (SNPs), promises to provide a comprehensive tool for analysing the human genome and identifying those genes and genomic regions contributing to the cancer phenotype. This review summarizes the various analytical methodologies in which SNPs are used and presents examples of how each of these methodologies have been used to locate genes and genomic regions of interest for various cancer types. Additionally many of the current SNP-analysing technologies will be reviewed with particular attention paid to the advantages and disadvantages of each and how each technology can be applied to the analysis of the genome for identifying cancer-related genes.
Introduction
Cellular growth is a carefully regulated process that requires a balance between genes that act to increase proliferation (oncogenes) and those which act to impede growth (tumor suppressors). Altered expression or activity of such growth controlling genes and their protein products can lead to abnormal cellular proliferation and tumor formation. Identifying and characterizing such genes is essential towards fully understanding cancer biology as well as elucidating new cancer drug targets from which novel therapeutics in the treatment of cancer can be developed. Additionally, continuing to discover new cancer genes will also aid in the development of methodologies aimed at cancer prevention and early diagnosis.
One of the most powerful methods available to identify genes involved in a disease process is through the implementation of genetic analyses where large numbers of polymorphic markers are used to locate a genomic region linked to a disease phenotype. Several types of polymorphic markers exist in the human genome and the type most amenable to large-scale, high-throughput analysis on a genome-wide level is single nucleotide polymorphisms (SNPs). A SNP is defined as a genomic locus where two or more alternative bases occur with appreciable frequency (>1%). SNPs are the most frequent type of variation in the human genome occurring once every several hundred base pairs throughout the genome (Cargill et al., 1999) and exhibit low mutation rates. They have been studied extensively for defining disease candidate gene regions, evolutionary studies, and establishing functional relationships between genotypic and phenotypic differences. Recently, the advent of newer technologies has increased the throughput of SNP genotyping while simultaneously decreasing the cost. Newer technologies have allowed the evaluation of SNPs, not just at a single locus, but on a genome-wide level at densities that had previously thought to be unobtainable. Such large scale, SNP analysis studies have met with some success in identifying genes and genomic regions involved in the development of various disease phenotypes. These SNP analysis technologies can be applied towards identifying new cancer genes. This review will specifically discuss how SNPs can be used to identify novel genes involved in the development of cancer and present specific examples of how SNP analysis has already been used to aid in the elucidation of genes involved in various cancer pathways. Furthermore, this review will describe many of the SNP technologies currently used and discuss their advantages, disadvantages, and applications in cancer research.
Applications of SNP genotyping

Direct association analysis
Direct association studies test the association between putative functional variants and disease risk. Typically, this involves the evaluation of nonsynonymous SNPs (those that result in an amino acid change) or possibly polymorphisms in regulatory regions which influence gene expression. The majority of disease alleles in Mendelian diseases are within coding SNPs and complex disease variants are thought to show a similar trend (Botstein and Risch, 2003) . Although Mendelian and complex traits had previously been considered to be separate phenomena, evidence is now accumulating that the two are much more related (Badano and Katsanis, 2002) . As a result, a more complete understanding of known causes of Mendelian disorders could provide useful information that would assist in the search for complex disease genes. The analysis of functional SNPs has the potential to be a powerful method of disease gene discovery since the number of common coding SNPs is only a fraction of the total number of common SNPs. The disadvantage of this approach is that a comprehensive list of functional polymorphisms within the gene of interest must be be identified either through SNP databases or experimental approaches such as DNA sequencing. Furthermore, as is often the case in cancer progression, uncharacterized de novo mutation could be contributing to the phenotype that may not be present within current SNP databases. There are numerous reports in the literature in which direct association studies have been used to study cancer. For example, two nonsynonymous SNPs within the MMP-9 gene have been shown to be associated with the risk of developing lung cancer with metastasis (Hu et al., 2005b) . Coding polymorphisms within the UGT1A7 have been shown to predict the response of colorectal cancer patients to capecitabine (Carlini et al., 2005) . The activity of thiopurine methyltransferase (TPMT), which catalyses the S-methylation of several thiopurine drugs used in chemotherapy including acute lymphoblastic leukemia (ALL), is defined by several coding polymorphisms (Otterness et al., 1997) and can be used to predict early treatment response in ALL (Stanulla et al., 2005) . Functional and common polymorphisms within the MTHFR gene have been linked to colorectal cancer (Ulvik et al., 2004; Jiang et al., 2005; Kono and Chen, 2005) , breast cancer (Gershoni-Baruch et al., 2000; Chen et al., 2005) , gastric cancer (Shen et al., 2001; Graziano et al., 2006) , and pancreatic cancer .
Direct association studies are usually performed within a candidate gene or genomic region. Candidate genes and regions are typically identified from linkage analysis, expression array analysis, knowledge of development and physiology; and comparative genomics. Tools such as the PANTHER database (Geesaman et al., 2003; Mi et al., 2005) and SNPEffect (Reumers et al., 2005) can be used to estimate the likelihood that a particular nonsynonymous coding SNP is causing a functional impact on the protein. The SNPSeek database (http://snp.wustl.edu/SNPseek/index.cgi) has now characterized over 90 000 coding SNPs in the exons of known genes. Alternatively, the SNP500Cancer database is specifically dedicated to the identification, validation, and characterization of polymorphisms within cancer-related genes (Packer et al., 2004) .
Linkage studies
Linkage studies are a family-based analysis approach to identify a disease gene. The method is based on the concept that, as a disease gene segregates through a family, genomic markers in close proximity to the disease gene will segregate in the same manner due to the lack of recombination between the disease allele and the marker. To use this method, families containing individuals affected by the disease are identified and polymorphic markers distributed throughout the genome are genotyped for each member of the family. The segregation of each marker is then compared to the segregation pattern of the disease phenotype within the family. A logarithm of the odds (LOD) score is then computed for each marker to indicate the likelihood that the marker is segregating with the disease gene. If the segregation of the polymorphic alleles matches the segregation of the disease phenotype, thus resulting in a high LOD score, it is an indication that the disease gene may be located near the polymorphic marker. A LOD score of 3.0 (1000-1 odds) is generally accepted to indicate that a particular marker is linked to the disease of interest. Traditionally, genome wide scans for linkage analysis were performed using several hundred microsatellites markers, often at a B10 cM density throughout the genome. The throughput of microsatellite-based genome wide scans is limited despite a moderate level of multiplexing of markers. However, the advent of newer genotyping technologies has allowed a dramatic increase in both the quality and quantity of linkage studies (John et al., 2004; Middleton et al., 2004; Murray et al., 2004; Sawcer et al., 2004; Schaid et al., 2004) . Products now exist for the simultaneous evaluation of thousands of SNPs on a genome wide level. As a result, a single researcher can perform approximately 24 genome wide scans within a single week. One disadvantage of SNPbased linkage study is that, due to their bi-allelic nature, SNPs have a maximal heterozygosity rate of 0.5 and thus have less resolution power than multiallelic microsatellites. This problem has been overcome by using a very high density of markers. In fact, most SNP-based linkage studies have utilized a panel of over 10 000 SNPs.
Numerous disease genes have been localized using SNP-based genome-wide scans including genes implicated in multiple sclerosis (Sawcer et al., 2004 (Sawcer et al., , 2005 , Pelizaeus-Merzbacher-like disease (Uhlenberg et al., 2004) , childhood severe retinal dystrophy (Janecke et al., 2004) , neonatal diabetes (Sellick et al., 2003) , age-related maculopathy (Jakobsdottir et al., 2005) , erythrokeratodermia (Saba et al., 2005) , arthrogryposisrenal dysfunction-cholestasis (ARC) syndrome (Gissen et al., 2004) , familial glucocorticoid deficiency type 2 (Metherell et al., 2005) , bipolar disorder , Charcot-Marie-Tooth disease (Shrimpton et al., 2004) and sudden infant death with dysgenesis of the testes (Puffenberger et al., 2004) . Owing to the sporadic nature of cancer development, few linkage studies have been performed using SNP-based approaches. Those studies that do exist mainly focused on prostate cancer owing to its familial clustering (Schaid et al., 2004; Larson et al., 2005) .
Indirect association studies
A major obstacle to performing linkage studies is that comprehensive, affected family samples can be difficult to obtain. It is generally easier to obtain case samples from unrelated individuals for the disease phenotype of interest. For such unrelated populations an indirect association study is preferable to evaluate the link between a particular gene and a disease phenotype. Indirect association studies are based on the concept that recombination seldom occurs between multiple SNPs that are in close proximity to each other and the disease gene. As a result, SNPs across a small region often exist as a block that is in linkage disequilibrium (LD). Since these multiple SNPs are essentially linked together as a single unit, evaluating the genotypes of any single SNP within that unit, will reflect the genotypes of all the SNPs within that LD block. With indirect association studies, the causative mutation is not directly evaluated, rather SNPs in the same LD block as the causative mutation are genotyped. If a SNP is in LD with the disease-causing mutation, then a difference should be observed between the case sample and a properly matched control population.
Indirect association studies can be performed in three different formats. The first format is the analysis of candidate genes. With this approach, candidate genes are chosen by any desired method such as literature searches, expression array analysis etc. SNPs are selected spanning the gene region such that at least one SNP per LD block is chosen for analysis. Several methods and software applications exist for the selection of such SNPs (Avi-Itzhak et al., 2003; Carlson et al., 2004; Halldorsson et al., 2004) . Each SNP is genotyped in a panel of case and control samples and the results are analysed to establish whether a difference exists between the populations. Typically, this analysis involves a comparison of allelic or genotypic frequencies for each group. A difference between the two groups may be indicative that the SNP is in LD with a disease-causing mutation of the phenotype being evaluated. Numerous examples of indirect association studies are present in the literature. Examples of significant associations include BRCA1 (Freedman et al., 2005) , BRCA2 (Freedman et al., 2004) , and CYP19 (Haiman et al., 2003) to breast cancer risk, CYP3A4 (Loukola et al., 2004) , IL1-RN (Lindmark et al., 2005) , and Toll-like receptors to prostate cancer risk, TP53BP2 (Ju et al., 2005) to gastric cancer risk, and DNA repair genes to skin cancer risk (Hao et al., 2004; Han et al., 2004a, b) .
A second format for indirect association studies is the analysis of a candidate gene region. Such a region may be defined by a linkage study or through the identification of a chromosomal abnormality. As with the candidate gene study, SNPs are selected based on regions in linkage disequilibrium with the causative mutation and span the region of interest. Differences between case and control populations are again indicative of a disease-causing mutation being in close proximity to the SNP evaluated.
Although indirect association studies of defined genomic regions is a powerful approach, this type of evaluation on the whole genome was initially cost and throughput prohibitive due to the need to analyse several hundred thousand genotypes per individual to be within LD distance of any potential gene mutation. However, with the development of novel SNP technologies, such genome-wide association studies are now possible. Current technologies are available which can evaluate >500 000 SNPs at a cost of 0.2 cents per genotype. As a result, SNPs spanning nearly all LD blocks within the human genome can now be evaluated.
To date, very few genome-wide association studies have been performed. The first notable large-scale genome association study utilized over 65 000 genotyped, gene-based SNPs in an attempt to identify genes associated with myocardial infarction (Ozaki et al., 2002) . Through their efforts, the authors identified a single SNP within intron 1 of the lymphotoxin-a (LTA) gene that displayed significant association with the disease. Further analysis revealed an additional, associated SNP that results in a threonine to asparagine amino acid change within LTA. In a second significant genome-wide association study, over 116 000 SNPs were genotyped to identify genes involved in the development of age-related macular degeneration (Klein et al., 2005) . Through this inquiry, a polymorphism located within the complement factor H (CFH) gene demonstrated a significant association. Subsequent analysis identified an amino acid polymorphism change, tyrosine to histidine, within CFH that is in LD with the originally identified risk allele. Although no large-scale genome-wide association studies have been performed to identify cancerrelated genes, smaller scale studies have been carried out. In one example, esophageal cancer was studied by analysing over 11 000 SNPs (Hu et al., 2005a) . Although this number of SNPs is not large enough to adequately cover the entire genome, the authors did identify polymorphisms within 33 different genes that displayed significant differences between case and control samples.
One consideration with this approach involves the evaluation and interpretation of such large-scale data sets. One key concern is that chance alone can produce a significant number of loci that appear to be associated with the phenotype of interest. For example, in the evaluation of 500 000 SNPs, a conservative cutoff P value of 0.01 may produce 5000 loci that show significant differences between cases and controls by chance alone. Setting a lower P-value threshold or compensating for multiple tests can reduce this issue, however, even with these corrections, the investigator must be prepared for a secondary analysis of a considerable number of loci.
Association studies can also be used in family structures, particularly those which do not lend themselves to traditional linkage studies, most typically in combination with linkage-in-the-transmission disequilibrium test (TDT) (Spielman et al., 1993; Spielman et al., 1994) . TDT is a nonparametric test that determines if the probability of transmission of a marker from parents to an affected offspring is >0.5, indicating that the marker is associated with the disease. TDT has been used to associate polymorphisms in MTHFR to the risk of developing childhood ALL (Krajinovic et al., 2004) , and to identify chromosomal regions which may contribute to susceptibility to endometrial adenocarcinoma (Roshani et al., 2005) in rat models.
A major issue with all indirect association studies is that other laboratories are often not able to replicate the observed results (Emahazion et al., 2001) . This can be due to two main factors. First is that the case and control populations are not appropriately matched and the results observed might be reflective of an intrinsic difference between the populations examined, such as ethnic differences, and not due to the phenotype being studied. Several approaches have been proposed to restrict errors of this nature (Geesaman et al., 2003; Hinds et al., 2004) . Alternatively, even with properly matched populations, chance alone will present differences between a case and control population unrelated to the phenotype under study. Since these results are more often publishable, there is an intrinsic bias to these situations in the literature. To reduce the occurrence of these situations, it is highly recommended that the original investigator replicate the study in an independent population. A similar result observed in a secondary population reduces the possibility that the results are occurring due to chance.
Allelic imbalances
Copy number alterations can lead to tumor development through the loss of tumor suppressor genes or the amplification of oncogenes. Identification of genomic regions containing copy number alterations is extremely informative for identifying novel cancer-related genes. Loss of heterozygosity and deletions can be identified through the evaluation of microsatellite markers within tumor and normal DNA from the same individual. Alternatively, amplified regions can be identified through densitometric analysis of Southern blots or by real-time PCR approaches.
The analysis of SNPs has provided several advantages over the aforementioned approaches. Since SNPs are abundantly present in the human genome, investigators can perform a denser analysis of a region of interest as compared to microsatellite markers. Additionally, due to the increased throughput of SNP technologies, analysis of tumors can be performed at a large scale and at a more rapid rate. Given that most genotyping technologies rely on a quantitative result, copy number alteration (both amplifications and deletions) can be evaluated based on the signal observed in the genotyping assay. An additional advantage of SNP genotyping is that tumor tissue DNA can often be analysed in the absence of normal tissue DNA from the same individual. Observing sequential SNPs that all yield homozygous genotypes can identify a region of LOH, although this is dependent on the allele frequency and number of SNPs evaluated. Alternatively, stretches of SNPs in which no signal is observed may be indicative of a microdeletion. Other copy number alterations may also be detected by comparing the signal associated with each genotyping assay to previously analysed normal DNA samples. Allelic imbalance studies utilizing SNPs have been performed in many tumor types including neuroblastomas (Maris et al., 2005) , papillary thyroid carcinomas (Stephens et al., 2005) , breast and ovarian cancer (Cvetkovic et al., 2004) , and adenocarcinomas (Koppert et al., 2004) .
Recently, there has been a tremendous increase in the use of genome-wide genotyping technologies to identify novel regions of copy number alterations. With this approach, SNPs spanning the entire genome are genotyped within tumor tissue DNA and, preferably, normal tissue DNA from the same individual. Each SNP is evaluated for any copy number alterations using the above approaches. Several software applications currently exist to facilitate this analysis (Huang et al., 2004; Lin et al., 2004; Herr et al., 2005) . The major advantage of this approach is that an investigator is not required to have any prior knowledge of the possible location of chromosomal alterations. Furthermore, given the high density of SNPs that can be evaluated on a genome wide level (>500 000), even the smallest regions of copy number alterations can be identified. This approach has opened a whole new area of cancer research. Such studies have included the evaluation of basal cell carcinomas (Teh et al., 2005) , Wilms' tumors (Yuan et al., 2005) , ovarian tumors (Thompson et al., 2005) , osteosarcomas , prostate cancer (Lieberfarb et al., 2003) , small cell and nonsmall cell lung carcinomas Zhao et al., 2004; Ishikawa et al., 2005) , breast cancer Herr et al., 2005) , squamous cell carcinomas , bladder tumors (Koed et al., 2005) , melanomas (Garraway et al., 2005) , acute lymphoblastic leukemias (Irving et al., 2005) , and acute myeloid leukemias . In nearly all of these cases, novel locations of allelic imbalance have been identified. Recently, this approach has even been used to identify copy number alterations in cultured human embryonic stem cells that are often observed in cancer (Maitra et al., 2005) .
SNP genotyping technologies
TaqMan assay (Applied Biosystems) TaqMan assays are based on a 5 0 nuclease assay (Livak et al., 1995; Livak, 1999) and have the advantage of combining PCR amplification and genotyping into a single reaction. Two probes that can hybridize to a given polymorphic sequence in an allele-specific manner are added to a single PCR reaction. Each probe carries a fluorescent reporter at the 5 0 end and a dye quencher at the 3 0 end. The quencher molecule suppresses the fluorescence of the reporter until a probe is hybridized to the appropriate SNP allele during amplification of the polymorphic locus. When the quencher molecule is cleaved by the 5 0 nuclease activity of Taq polymerase the reporter molecule is released from the quencher molecule and a fluorescent signal is produced. The genotype of that SNP is determined by comparing the fluorescent signal for each of the two allele-specific reporter dyes, typically at the end of the amplification.
One of the clear advantages of the TaqMan assay is its ability to combine the PCR amplification and genotyping assay into a single step, greatly reducing sample processing. Even though TaqMan genotyping cannot be multiplexed and costs are higher when compared to other multiplexing approaches, this cost can be offset by the reduction in labor associated with assay setup and execution. Furthermore, the capital equipment cost for TaqMan assays is generally one-half to one-third the cost of all other approaches and should be factored in when determining the overall genotyping cost.
SNPStream assay (Orchid Cellmark/Beckman Coulter)
The SNPStream genotyping assay is based on the technique of single-base extension (SBE) (Nikiforov et al., 1994; Bell et al., 2002) . Briefly, for each polymorphic site amplified by multiplex PCR, primers containing a unique 5 0 tag sequence are hybridized one base pair upstream of the SNP. Dideoxy nucleotides are added with each ddNTP for each SNP allele labeled with a different fluorescent color. For example, for a C/T SNP, the ddCTP is labeled with Bodipy-Fluorescein and the ddTTP is labeled with the fluorophore TAMRA. The mix containing the hybrized primers and labeled dideoxy nucleotides are extended one base into the target SNP. These single-base extended products are hybridized to a plate that contains, in each well, an array of oligonucleotides complementary to each of the extension primer tags used. Upon hybridization of the extension product to its complementary tag, the 2-color fluorescence of each spot within each well is determined. Each SNP is identified by its position within the array and genotypes are determined by the relative 2-color fluorescence observed at each position.
The SBE approach is a relative straightforward assay in which all pre-hybridization steps are performed in a single-tube. Plates containing wells arrayed with either 12 or 48 spotted oligo tags can be obtained allowing for significant levels of multiplexing. One of the disadvantages is that since the assay results are based on the relative fluorescent signal from two labeled terminators, SNPs of a similar type must be grouped together. For example, the user must multiplex all C/T type SNPs together and not include other SNP types. Depending on the SNP study, it is likely that the user will be required to perform the assay at a submaximal level of multiplexing, reducing the cost-efficiency of the assay.
iPLEX assay (Sequenom) Sequenom has recently released a homogenous genotyping assay, termed iPLEX (http://www.sequenom.com/ iPLEX/index2.php), which takes advantage of the molecular weight differences of single base extension products. In this case, the single base extension reaction, outlined above, is run with unlabeled ddNTPs, resulting in two extension products of different molecular weights based on the allele incorporated. The reaction is analysed by MALDI-TOF mass spectrometry analysis and peak heights are indicative of the genotype.
One issue with this approach is that the molecular weight difference between SBE products can be very small, depending on the SNP alleles to be analysed. This can be as little as a 9 Da difference for A/G SNPs. To address this potential problem, Sequenom has created terminators that have been modified to increase the mass differences between the SBE products. As a result, the mass difference between extension products is a minimum of 16 Da and a maximum of 79 Da thus improving SNP allele discrimination. Owing to the fact that the analysis of products is based on molecular weight and not fluorescence, all four terminator bases may be added to the reaction. The main limitation is the number of products that can be analysed simultaneously by MALDI-TOF MS. Multiplexing of 24 polymorphic loci is typical on this system.
The iPLEX approach provides the user with a moderate level of multiplexing in a single tube assay. The assay, however, has numerous steps in which reagents must be added and as a result throughput is diminished. Another consideration is that MALDI-TOF mass spectrometry can be a very sensitive assay and thus careful attention must be made to avoid contaminants.
GoldenGate genotyping assay (Illumina)
The GoldenGate Assay is a combination of an oligonucleotide ligation (OLA) (Landegren et al., 1988) and allele-specific extension reaction analysed with the Illumina core technology, which analyses thousands of differentially labeled beads simultaneously. For each SNP, three oligonucleotides are synthesized; two oligos are allele specific (ASO) with a universal PCR primer sequence located at the 5 0 end (P1 and P2). The third primer is a locus specific oligo (LSO) with a 5 0 universal primer sequence (P3), a unique tag sequence, and a sequence complementary to a region downstream of the SNP site. All three oligos are added to genomic DNA and the mixture undergos an extension and ligation reaction. If an ASO is a perfect match to the SNP allele it will be extended and then ligated to the LSO via the complementary SNP site region on the LSO. The mixture is then subjected to PCR using P1 and P2 primers, each labeled with different fluorophores, and the universal P3 primer. Purified PCR products are hybridized to a mixture of bead types. Each bead type contains unique bead sequences complementary to the tags present on the P3 LSO and therefore each bead type represents the assay results for one particular SNP. The genotypes are determined by the relative fluorescence of the two labels observed for each bead. The Applied Biosystems SNPlex system uses a similar OLA/PCR approach but PCR products are labeled with fluorescent reporter probes and separated by capillary electrophoresis. The advantage of these systems is that a large number of SNPs can be multiplexed together (1536 for GoldenGate, 48 for SNPlex). However, each of these protocols can be rather labor intensive with multiple steps.
GeneChip Human Mapping assays (Affymetrix)
Affymetrix has commercialized several products for the analysis of SNPs on a genome-wide level. The challenge faced with genome-wide genotyping is that, as the number of SNPs increases, multiplex PCR becomes technically difficult. An alternative approach is to reproducibly amplify a subset of the human genome through a genome complexity reduction step (Jordan et al., 2002; Kennedy et al., 2003; Matsuzaki et al., 2004) . The reduced genome is of sufficient complexity to contain thousands of SNP loci, yet not so complex as to prevent the analysis of these SNPs. Several methods have been documented to yield reduced complexity genomes including DOP-PCR, Alu-PCR and RAPD-PCR. Affymetrix has utilized another method, adaptor-PCR, to create a reduced-complexity genome for SNP analysis. Genomic DNA is digested with a restriction enzyme (e.g. XbaI) and universal adaptor sequences are annealed to the sticky ends. The fragments are then amplified by PCR, using a single primer recognizing the adaptor-ligated sequences. The reaction conditions are such that only a subset of the fragments is amplified. As a result, a reproducible subset of the genome is isolated. The fragments are labeled and hybridized to a chip containing oligos that allow genotyping of the SNPs present within the reduced genome. Owing to the nature of the genome-complexity reduction approach, it can be scaled to higher levels of SNP genotyping by simply altering the restriction enzyme or PCR conditions to create a higher complexity subset and a greater number of amplified SNPs. This approach has been used in the creation of the GeneChip Human Mapping 100K and 500 K products for the analysis of over 100 000 and 500 000 SNPs, respectively.
As expected, the assay protocol requires numerous steps although portions of the procedure can be automated. With a manual setup the number of samples that can be processed are 12-24 within a 3-to 4-dayperiod. One of the major disadvantages of the Affymetrix assay is that it requires high-quality DNA since the genome-complexity reduction step is dependent on intact restriction enzyme sites. Degraded DNA samples can lead to lower call rates or unsuccessful assays. This is of critical importance when dealing with tumor DNA or older DNA samples which are often degraded. A second disadvantage is the fact that Affymetrix recommends that the sample to be analysed must be native genomic DNA and cannot be the result of genome amplification methods such as primer extension preamplification (Zhang et al., 1992) or multiple strand displacement (Dean et al., 2002) . However, this is seldom an issue since only 250 ng of DNA is required for the process.
Infinium genotyping assay (Illumina)
Illumina has released an alternative approach to wholegenome genotyping, which combines its BeadChip arrays with an allele-specific extension reaction (Gunderson et al., 2005) . Currently, the Infinium assay is capable of analysing over 100 000 SNPs distributed in an exon-centric manner across the genome. To perform the assay, genomic DNA is amplified by a non-PCR approach in an isothermal reaction. Amplified DNA is fragmented and hybridized to a mixture of bead types. Two bead types are dedicated for the genotyping of each SNP site resulting in over 200 000 bead types for the analysis of over 100 000 SNPs. To each pair of beads a B50-mer locus-specific oligo is attached in which the last nucleotide is positioned at the polymorphic base. Upon hybridization to the amplified DNA, the beadbound primers undergo an extension reaction in the presence of unlabeled and labeled nucleotides. Primers with a mismatch at the SNP site will fail to extend and not be labeled whereas those with a perfect match will extend and become labeled. The reporter signal associated with each bead is determined by imaging each of the 200 000 bead types. The relative signal observed for each pair of beads is used to determine the genotype of each SNP.
Similar to the Affymetrix assay, the Infinium assay contains numerous steps and requires several days to complete. The throughput levels are at similar levels as well. The current Infinium assay product is capable of analysing over 100 000 SNPs. Products have recently been released for the analysis of over 250 000 SNPs. One significant advantage of the Infinium assay over the Affymetrix system is that it can utilize DNA that is partially degraded making this assay more amenable for the analysis of tumor DNA or older DNA samples.
Future directions
Advances in SNP-analysing technologies will undoubtedly increase the sensitivity with which genomic changes that influence the development of cancer can be detected. With this increase in sensitivity, it is expected that the number of novel cancer genes and pathways that will be identified will increase concomitantly. Additionally, as existing technologies are improved and novel technologies are developed, throughput is expected to increase and costs are expected to decrease, allowing for more comprehensive and more numerous studies to be completed, thereby contributing to the identification of cancer-related genes at a more rapid pace. For example, products are currently becoming available which can evaluate thousands of nonsynonymous coding SNPs simultaneously. As this technology becomes a reality, genome-wide direct association studies will now become feasible.
As the sensitivity and throughput of SNP analysis increases and the cost decreases, genotypic analysis is expected to transition from the laboratory to the clinic. Such a transition has already been seen with diagnostic products available in a clinical setting for genotyping several drug metabolizing enzymes and cancer genes. With the emphasis on developing simpler SNP assays that can simultaneously evaluate larger numbers of SNPs, it would not be surprising to see the development of a product, which would consolidate several predictive cancer-related polymorphisms and mutations into a single diagnostic test. For example, with a single tumor sample, one might be able to simultaneously establish the genotypes of all drug metabolizing enzymes (e.g. CYP450 genes, NAT1/2, UGT genes, and glutathione transferases) as well as genotype all known polymorphisms and mutations in oncogenes (PI3K, AKT, and STAT3) and tumor suppressor genes (e.g. p53, Rb, and p16). Additionally, allelic imbalances could also be evaluated for either individual oncogenes (myc, mdm2) or on a genome-wide level.
SNP analysis is an invaluable tool for deciphering the genetic complexities responsible for the development of cancer. It promises to assist in the identification of novel cancer-related genes as well as in the development of new cancer therapeutics and diagnostic tests aimed at early cancer detection and even further, for predicting an individual's likelihood for developing cancer. Implementing these future directions into reality will help to save countless lives.
